Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma

Overview

Journal Oncotarget

Specialty Oncology

Date 2013 Aug 1

PMID 23900284

Citations 24

Authors

Zhigang Xie

Jayantha Gunaratne

Lip Lee Cheong

Shaw Cheng Liu

Tze Loong Koh

Gaofeng Huang

Walter P Blackstock

Wee Joo Chng

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) is characterized by recurrent chromosomal translocations. MMSET, identified by its fusion to the IgH locus in t(4;14) MM, is universally overexpressed in t(4;14) MM. In order to identify cell surface biomarkers associated with t(4;14) MM for small molecule or antibody based therapies, we knocked down MMSET expression with shRNA and generated a cell line pair from KMS11, a t(4;14) MM cell line. We used quantitative mass spectrometry to identify plasma membrane proteins associated with MMSET overexpression. Using this approach, 50 cell surface proteins were identified as differentially expressed between KMS11 and KMS11/shMMSET. Western blot and flow cytometry analysis indicated SLAMF7 was over-expressed in t(4;14) MM cell lines and down-regulated by MMSET shRNAs. SLAMF7 expression was also confirmed in primary t(4;14) MM samples by flow cytometry analysis. Quantitative RT-PCR and ChIP analysis indicated MMSET might regulate the transcription level of SLAMF7 and be an important functional element for SLAMF7 promoter activity. Furthermore, SLAMF7 shRNA could induce G1 arrest or apoptosis and reduce clonogenetic capacity in t(4;14) MM cells. Overall, these results illustrated SLAMF7 might be a novel cell surface protein associated with t(4;14) MM. It is potential to develop t(4;14) MM targeted therapy by SLAMF7 antibody mediated drug delivery.

Citing Articles

The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.

Desantis V, Savino F, Scaringella A, Potenza M, Nacci C, Frassanito M J Clin Med. 2022; 11(9).

PMID: 35566637 PMC: 9105926. DOI: 10.3390/jcm11092513.

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.

Cho S, Xing L, Anderson K, Tai Y Cancers (Basel). 2021; 13(23).

PMID: 34885245 PMC: 8657018. DOI: 10.3390/cancers13236136.

Genome Instability in Multiple Myeloma: Facts and Factors.

Aksenova A, Zhuk A, Lada A, Zotova I, Stepchenkova E, Kostroma I Cancers (Basel). 2021; 13(23).

PMID: 34885058 PMC: 8656811. DOI: 10.3390/cancers13235949.

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma.

Mohan M, Maatman T, Schinke C Cancers (Basel). 2021; 13(19).

PMID: 34638393 PMC: 8507719. DOI: 10.3390/cancers13194909.

Prognostic and predictive biomarker developments in multiple myeloma.

Wallington-Beddoe C, Mynott R J Hematol Oncol. 2021; 14(1):151.

PMID: 34556161 PMC: 8461914. DOI: 10.1186/s13045-021-01162-7.

References

Bergsagel P, Kuehl W . Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003; 194:96-104. DOI: 10.1034/j.1600-065x.2003.00052.x. View

Mann M . Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006; 7(12):952-8. DOI: 10.1038/nrm2067. View

Bergsagel P, Kuehl W . Chromosome translocations in multiple myeloma. Oncogene. 2001; 20(40):5611-22. DOI: 10.1038/sj.onc.1204641. View

Cox J, Mann M . MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008; 26(12):1367-72. DOI: 10.1038/nbt.1511. View

Garlisi C, Uss A, Xiao H, Tian F, Sheridan K, Wang L . A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol. 2001; 24(1):90-98. DOI: 10.1165/ajrcmb.24.1.4224. View

van Rhee F, Szmania S, Dillon M, van Abbema A, Li X, Stone M . Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009; 8(9):2616-24. PMC: 2748787. DOI: 10.1158/1535-7163.MCT-09-0483. View

Dib A, Gabrea A, Glebov O, Bergsagel P, Kuehl W . Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr. 2008; (39):25-31. PMC: 2737184. DOI: 10.1093/jncimonographs/lgn011. View

Godar S, Ince T, Bell G, Feldser D, Liu Donaher J, Bergh J . Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008; 134(1):62-73. PMC: 3222460. DOI: 10.1016/j.cell.2008.06.006. View

Marango J, Shimoyama M, Nishio H, Meyer J, Min D, Sirulnik A . The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood. 2007; 111(6):3145-54. PMC: 2265454. DOI: 10.1182/blood-2007-06-092122. View

10.

Bergsagel P, Kuehl W . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23(26):6333-8. DOI: 10.1200/JCO.2005.05.021. View

11.

Shipman C, Rogers M, Apperley J, Russell R, Croucher P . Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997; 98(3):665-72. DOI: 10.1046/j.1365-2141.1997.2713086.x. View

12.

Lee J, Boles K, Mathew P . Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol. 2004; 34(10):2791-9. DOI: 10.1002/eji.200424917. View

13.

Lee S, Buhimschi I, Dulay A, Ali U, Zhao G, Abdel-Razeq S . IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes. J Immunol. 2011; 186(5):3226-36. PMC: 3800180. DOI: 10.4049/jimmunol.1003587. View

14.

Lee J, Mathew S, Vaidya S, Kumaresan P, Mathew P . CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol. 2007; 179(7):4672-8. DOI: 10.4049/jimmunol.179.7.4672. View

15.

Cheng T, Roffler S . Membrane-tethered proteins for basic research, imaging, and therapy. Med Res Rev. 2008; 28(6):885-928. DOI: 10.1002/med.20127. View

16.

Veillette A . NK cell regulation by SLAM family receptors and SAP-related adapters. Immunol Rev. 2006; 214:22-34. DOI: 10.1111/j.1600-065X.2006.00453.x. View

17.

Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

18.

Ong S, Mann M . A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc. 2007; 1(6):2650-60. DOI: 10.1038/nprot.2006.427. View

19.

Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy Jr J . A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2002; 101(6):2374-6. DOI: 10.1182/blood-2002-09-2801. View

20.

Tai Y, Dillon M, Song W, Leiba M, Li X, Burger P . Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2007; 112(4):1329-37. PMC: 2515112. DOI: 10.1182/blood-2007-08-107292. View